Champions Oncology (CSBR) 10-Q 18 Mar 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Jan. 31, 2019	Mar. 14, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jan. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Registrant Name	CHAMPIONS ONCOLOGY, INC.
Entity Central Index Key	0000771856
Current Fiscal Year End Date	--04-30
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Trading Symbol	CSBR
Entity Common Stock, Shares Outstanding		11,615,272

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jan. 31, 2019	Apr. 30, 2018
Statement of Financial Position [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 3,310
Current assets:
Cash	3,310	$ 856
Accounts receivable, net	3,919	3,917
Prepaid expenses and other current assets	298	287
Total current assets	7,527	5,060
Restricted cash	0	150
Property and equipment, net	2,578	2,083
Other long term assets	137	116
Goodwill	669	669
Total assets	10,911	8,078
Current liabilities:
Accounts payable	2,116	2,154
Accrued liabilities	641	569
Current portion of capital lease	224	26
Deferred revenue	4,723	4,704
Total current liabilities	7,704	7,453
Deferred rent	733	454
Capital lease, net of current portion	0	17
Other non-current liabilities	151	151
Total liabilities	8,588	8,075
Stockholders’ equity:
Common stock, $.001 par value; 200,000,000 shares authorized; 11,612,700 and 11,277,675 shares issued and 11,612,700 and 11,003,228 shares outstanding as of January 31, 2019 and April 30, 2018, respectively	12	11
Treasury stock, at cost, nil and 269,685 common shares as of January 31, 2019 and April 30, 2018, respectively	0	(1,252)
Additional paid-in capital	72,756	72,070
Accumulated deficit	(70,445)	(70,826)
Total stockholders’ equity	2,323	3
Total liabilities and stockholders’ equity	$ 10,911	$ 8,078

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - $ / shares	Jan. 31, 2019	Apr. 30, 2018
Statement of Financial Position [Abstract]
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	11,612,700	11,277,675
Common Stock, shares outstanding	11,612,700	11,003,228
Treasury Stock, common shares	0	269,685

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Income Statement [Abstract]
Oncology services revenue	$ 6,430,000	$ 5,082,000	$ 19,348,000	$ 15,319,000
Costs and operating expenses:
Cost of oncology services	3,429,000	2,473,000	9,963,000	7,737,000
Research and development	1,269,000	1,045,000	3,550,000	3,308,000
Sales and marketing	879,000	627,000	2,138,000	1,862,000
General and administrative	1,223,000	1,004,000	3,311,000	3,167,000
Total costs and operating expenses	6,800,000	5,149,000	18,962,000	16,074,000
Income (loss) from operations	(370,000)	(67,000)	386,000	(755,000)
Other expense:
Other (income) expense	(1,000)	7,000	5,000	71,000
Total other (income) expense	(1,000)	7,000	5,000	71,000
Income (loss) before provision for income taxes	(369,000)	(74,000)	381,000	(826,000)
Provision for income taxes	0	2,000	0	18,000
Net income (loss)	$ (369,000)	$ (76,000)	$ 381,000	$ (844,000)
Net income (loss) per common share outstanding
Net income (loss) per common share outstanding, basic (in dollars per share)	$ (0.03)	$ (0.01)	$ 0.03	$ (0.08)
Net income (loss) per common share outstanding, diluted (in dollars per share)	$ (0.03)	$ (0.01)	$ 0.03	$ (0.08)
Weighted average common shares outstanding
Weighted average common shares outstanding, basic (in shares)	11,508,180	10,994,434	11,257,314	10,987,797
Weighted average common shares outstanding, diluted (in shares)	11,508,180	10,994,434	13,909,063	10,987,797

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance (shares) at Apr. 30, 2018		11,003,228	269,685
Beginning balance at Apr. 30, 2018	$ 3,000	$ 11,000	$ (1,252,000)	$ 72,070,000	$ (70,826,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	75,000			75,000
Issuance of common stock for services (in shares)		4,762
Issuance of common stock on exercise of stock options and warrants (in shares)		20,000
Issuance of common stock on exercise of stock options and warrants				42,000
Net income	483,000				483,000
Ending balance (shares) at Jul. 31, 2018		11,027,990	269,685
Ending balance at Jul. 31, 2018	603,000	$ 11,000	$ (1,252,000)	72,187,000	(70,343,000)
Beginning balance (shares) at Apr. 30, 2018		11,003,228	269,685
Beginning balance at Apr. 30, 2018	3,000	$ 11,000	$ (1,252,000)	72,070,000	(70,826,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	381,000
Ending balance (shares) at Jan. 31, 2019		11,612,700	0
Ending balance at Jan. 31, 2019	2,323,000	$ 12,000	$ 0	72,756,000	(70,445,000)
Beginning balance (shares) at Jul. 31, 2018		11,027,990	269,685
Beginning balance at Jul. 31, 2018	603,000	$ 11,000	$ (1,252,000)	72,187,000	(70,343,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	88,000			88,000
Issuance of common stock on exercise of stock options and warrants (in shares)		446,815	269,685
Issuance of common stock on exercise of stock options and warrants	1,034,000		$ 1,252,000	(218,000)
Net income	267,000				267,000
Ending balance (shares) at Oct. 31, 2018		11,474,805	0
Ending balance at Oct. 31, 2018	1,992,000	$ 11,000	$ 0	72,057,000	(70,076,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	335,000			335,000
Issuance of common stock on exercise of stock options and warrants (in shares)		137,895
Issuance of common stock on exercise of stock options and warrants	365,000	$ 1,000		364,000
Net income	(369,000)				(369,000)
Ending balance (shares) at Jan. 31, 2019		11,612,700	0
Ending balance at Jan. 31, 2019	$ 2,323,000	$ 12,000	$ 0	$ 72,756,000	$ (70,445,000)

UNAUDITED CONDENSED CONSOLIDA_2

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Operating activities:
Net income (loss)	$ 381,000	$ (844,000)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Stock-based compensation and modification expense	498,000	848,000
Issuance of common stock for services	8,000	15,000
Depreciation and amortization expense	433,000	253,000
Provision for doubtful accounts	53,000	0
Deferred rent	279,000	302,000
Changes in operating assets and liabilities:
Accounts receivable	(55,000)	(669,000)
Prepaid expenses and other current assets	(11,000)	115,000
Other long term assets	21,000	0
Accounts payable	(46,000)	124,000
Accrued liabilities	72,000	(320,000)
Deferred revenue	19,000	(1,059,000)
Net cash provided by (used in) operating activities	1,610,000	(1,235,000)
Investing activities:
Purchase of property and equipment	(693,000)	(1,017,000)
Net cash used in investing activities	(693,000)	(1,017,000)
Financing activities:
Proceeds from exercise of options and warrants	1,440,000	38,000
Capital lease payments	(53,000)	(19,000)
Net cash provided by financing activities	1,387,000	19,000
Increase/(decrease) in cash and restricted cash	2,304,000	(2,233,000)
Cash and restricted cash at beginning of period	1,006,000	3,295,000
Cash and restricted cash at end of period	3,310,000	1,062,000
Non-cash investing activities:
Purchase equipment under capital lease	$ 235,000	$ 0

Organization, Use of Estimates

Organization, Use of Estimates and Basis of Presentation	9 Months Ended
	Jan. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Use of Estimates and Basis of Presentation	Organization, Use of Estimates and Basis of Presentation Champions Oncology, Inc. (the “Company”) is engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Translational Oncology Solutions (“TOS”) and Personalized Oncology Solutions (“POS”). The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings. POS assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The Company has two operating subsidiaries: Champions Oncology (Israel), Limited and Champions Biotechnology U.K., Limited. For the three and nine months ended January 31, 2019 and 2018 , there were no revenues earned by these subsidiaries. The Company’s foreign subsidiaries functional currency is the U.S. dollar. Transaction gains and losses are recognized in earnings. The Company is subject to foreign exchange rate fluctuations in connection with the Company’s international operations. These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. All significant intercompany transactions and accounts have been eliminated. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, or GAAP, has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended April 30, 2018 , as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Annual Report on Form 10-K for the year ended April 30, 2018 . The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Certain amounts in the prior periods presented have been reclassified to conform to the current period financial statement presentation. These reclassifications have no effect on previously reported net income.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Jan. 31, 2019
Accounting Policies [Abstract]
Significant Accounting Policies	e Recognition All revenue is generated from contracts with customers. The Company's arrangements are service type contracts that mainly have a duration of less than a year. The Company recognizes revenue when control of these services is transferred to the customer in an amount, referred to as the transaction price, that reflects the consideration to which the Company is expected to be entitled in exchange for those services. The Company determines revenue recognition utilizing the following five steps: (1) identification of the contract with a customer, (2) identification of the performance obligations in the contract (promised goods or services that are distinct), (3) determination of the transaction price, (4) allocation of the transaction price to the performance obligations, and (5) recognition of revenue when, or as, the Company transfers control of the product or service for each performance obligation. The Company records revenues net of any tax assessments by governmental authorities, such as value added taxes, that are imposed on and concurrent with specific revenue generating transactions. Pharmacology Study, POS Services and Other Services The Company generally enters into contracts with customers to provide oncology services with payments based on fixed-fee arrangements. At contract inception, the Company assesses the services promised in the contracts with customers to identify the performance obligations in the arrangement. The Company's fixed-fee arrangements for oncology services are considered a single performance obligation because the Company provides a highly-integrated service. The Company recognizes revenue over time using a progress-based input method since there is no single output measure that would fairly depict the transfer of control over the life of the performance obligation. Revenue is recognized for the single performance obligation over time due to the Company's right to payment for work performed to date and the performance does not create an asset with an alternative use. The Company recognizes revenue as portions of the overall performance obligation are completed as this best depicts the progress of the performance obligation. Variable Consideration In some cases, contracts provide for variable consideration that is contingent upon the occurrence of uncertain future events, such as the success of the initial performance obligation. Variable consideration is estimated at the expected value or at the most likely amount depending on the type of consideration. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimate of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available to the Company. Trade Receivables, Unbilled Services and Deferred Revenue In general, billings and payments are established by contractual provisions including predetermined payment schedules, which may or may not correspond to the timing of the transfer of control of the Company's services under the contract. In general, the Company's intention in its invoicing (payment terms) is to maintain cash neutrality over the life of the contract. Upfront payments, when they occur, are intended to cover certain expenses the Company incurs at the beginning of the contract. Neither the Company nor its customers view such upfront payments and contracted payment schedules as a means of financing. Unbilled services primarily arise from timing of payment terms and when an input method of revenue recognition is utilized and revenue recognized exceeds the amount billed to the customer. Deferred revenue consists of unearned payments received in excess of revenue recognized. As the contracted services are subsequently performed and the associated revenue is recognized, the deferred revenue balance is reduced by the amount of the revenue recognized during the period. Deferred revenue is classified as a current liability on the condensed consolidated balance sheet as the Company expects to recognize the associated revenue in less than one year. Accounting Pronouncements Being Evaluated In August 2018, the FASB issued ASU 2018-15, which amends ASC 350-40, Intangibles—Goodwill and Other—Internal-Use Software, to address a customer’s accounting for implementation costs incurred in a cloud computing arrangement ("CCA") that is a service contract. This update aligns the accounting for costs incurred to implement a CCA that is a service arrangement with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The update is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption of the amendments in this update is permitted, including adoption in any interim period. We are currently assessing the impact of this update on our consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses". This update requires immediate recognition of management’s estimates of current expected credit losses ("CECL"). Under the prior model, losses were recognized only as they were incurred. The new model is applicable to all financial instruments that are not accounted for at fair value through net income. The standard is effective for fiscal years beginning after December 15, 2019 for public entities. Early adoption is permitted. We are currently assessing the impact of this update on our consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, "Leases". The Company is in the process of finalizing its evaluation of current leases and quantifying the impact to its balance sheet. The Company expects that the adoption of the standard will have a material impact on its consolidated balance sheet for the recognition of certain operating leases as right-of-use assets and lease liabilities. The Company does not expect the adoption of this standard to have a material impact on its consolidated statements of operations or cash flows. The Company will adopt the new accounting standard using the modified retrospective transition option on adoption on May 1, 2019. Recently Adopted Accounting Pronouncements In June 2018, the FASB issued ASU 2018-07, "Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting". This ASU expands the scope of Topic 718, Compensation—Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Under the new guidance, the existing employee guidance will apply to nonemployee sharebased transactions (as long as the transaction is not effectively a form of financing), with the exception of specific guidance related to the attribution of compensation cost. The cost of nonemployee awards will continue to be recorded as if the grantor had paid cash for the goods or services. The new accounting guidance will be effective for the Company on May 1, 2019. The Company has adopted this new rule beginning with its financial reporting for the quarter ended January 31, 2019. The adoption had no material impact on our consolidated financial statements. In August 2018, the Securities and Exchange Commission issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to the Company’s financial reporting is the inclusion of the annual disclosure requirement of changes in stockholders’ equity in Rule 3-04 of Regulation S-X to interim periods. The Company has adopted this new rule beginning with its financial reporting for the quarter ended October 31, 2018. On November 17, 2016, the FASB issued ASU No. 2016-18, "Restricted Cash (a consensus of the FASB Emerging Issues Task Force)" ("ASU 2016-18"), which addresses classification and presentation of changes in restricted cash on the statement of cash flows. ASU 2016-18 requires an entity's reconciliation of the beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include in cash and cash equivalents amounts generally described as restricted cash and restricted cash equivalents. ASU 2016-18 is effective for public business entities for annual and interim periods in fiscal years beginning after December 15, 2017. The Company adopted ASU 2016-18 on May 1, 2018. See "Note 2. Summary of Significant Accounting Policies" for additional disclosure. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. The new standard attempts to reduce diversity in practice in how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU No. 2016-15 provides guidance on eight specific cash flow issues. The new guidance was effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years. The Company adopted this update on May 1, 2018 and did not have a material impact on our consolidated financial statements. In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with customers ("ASU 2014-09"). The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The Company adopted ASU 2014-09 on May 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption and by recognizing the cumulative effect of applying the standard as an adjustment to the Company’s Balance Sheet. The adoption of this update did not have a material measurement impact on our consolidated financial statements. See "Note 4. Revenue from Contracts with Customers" for more information.

Accounts Receivable, Unbilled S

Accounts Receivable, Unbilled Services and Deferred Revenue	9 Months Ended
	Jan. 31, 2019
Receivables [Abstract]
Accounts Receivable, Unbilled Services and Deferred Revenue	Accounts Receivable, Unbilled Services and Deferred Revenue Accounts receivable and unbilled services were as follows (in thousands): January 31, 2019 April 30, 2018 (unaudited) Accounts receivable $ 2,367 $ 1,827 Unbilled services 1,565 2,103 Total accounts receivable and unbilled services 3,932 3,930 Less allowance for doubtful accounts (13 ) (13 ) Total accounts receivable, net $ 3,919 $ 3,917 Deferred revenue was as follows (in thousands): January 31, 2019 April 30, 2018 (unaudited) Deferred revenue $ 4,723 $ 4,704 Deferred revenue is shown as a current liability on the Company's balance sheet.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
	Jan. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	Revenue from Contracts with Customers Oncology Services Revenue The Company adopted ASC 606 on May 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. The reported results for the three and nine months ended January 31, 2019 reflect the application of ASC 606, while the reported results for the three and nine months ended January 31, 2018 were prepared under ASC 605 - Revenue Recognition and other authoritative guidance in effect for this period. In accordance with ASC 606, revenue is now recognized when, or as, a customer obtains control of promised services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. A performance obligation is a promise (or a combination of promises) in a contract to transfer distinct goods or services to a customer and is the unit of accounting under ASC 606 for the purposes of revenue recognition. A contract's transaction price is allocated to each separate performance obligation based upon the standalone selling price and is recognized as revenue, when, or as, the performance obligation is satisfied. The majority of the Company's contracts have a single performance obligation because the promise to transfer individual services is not separately identifiable from other promises in the contracts, and therefore, is not distinct. The majority of the Company's revenue arrangements are service contracts that are complete within a year or less. There are a few contracts that range in duration between 1 and 3 years. Substantially all of the Company's performance obligations, and associated revenue, are transferred to the customer over time. Most of the Company's contracts can be terminated by the customer without cause. In the event of termination, the Company's contracts provide that the customer pay the Company for services rendered through the termination date. The Company generally receives compensation based on a predetermined invoicing schedule relating to specific milestones for that contract. In addition, in certain instances a customer contract may include forms of variable consideration such as performance increases or other provisions that can increase or decrease the transaction price. This variable consideration is generally awarded upon achievement of certain performance metrics. For the purposes of revenue recognition, variable consideration is assessed on a contract-by-contract basis and the amount to be recorded is estimated based on the assessment of the Company's anticipated performance and consideration of all information that is reasonably available. Variable consideration is recognized as revenue if and when it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved in the future. Amendments to contracts are common. The Company evaluates each amendment which meets the criteria of a contract modification under ASC 606. Each modification is further evaluated to determine whether the contract modification should be accounted for as a separate contract or as a continuation of the original agreement. The Company accounts for amendments as a separate contract as they meet the criteria under ASC 606-10-25-12. The following tables represents disaggregated revenue for the three and nine months ended January 31, 2019 and 2018 : Three Months Ended Nine Months Ended January 31, 2019 2018 2019 2018 Pharmacology services $ 5,988 $ 4,447 $ 18,037 $ 13,600 Personalized oncology services 416 259 1,024 1,077 Other 26 376 287 642 Total oncology services revenue $ 6,430 $ 5,082 $ 19,348 $ 15,319 Contract Balances Contract assets include unbilled amounts typically resulting from revenue recognized in excess of the amounts billed to the customer for which the right to payment is subject to factors other than the passage of time. These amounts may not exceed their net realizable value. Contract assets are classified as current. Contract liabilities consist of customer payments received in advance of performance and billings in excess of revenue recognized, net of revenue recognized from the balance at the beginning of the period. Contract assets and liabilities are presented on the balance sheet on a net contract-by-contract basis at the end of each reporting period.

Property and Equipment

Property and Equipment	9 Months Ended
	Jan. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment is recorded at cost and primarily consists of laboratory equipment, leasehold improvements, furniture and fixtures, and computer equipment and software. Depreciation and amortization is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following (table in thousands): January 31, April 30, (unaudited) Furniture and fixtures $ 127 $ 73 Computer equipment and software 1,086 973 Laboratory equipment 3,241 2,490 Assets in progress 25 15 Total property and equipment 4,479 3,551 Less: Accumulated depreciation (1,901 ) (1,468 ) Property and equipment, net $ 2,578 $ 2,083 Depreciation and amortization expense, excluding expense recorded under capital lease, was $127,000 and $98,000 for the three months ended January 31, 2019 and 2018 , respectively, and $ 353,000 and $ 233,000 for the nine months ended January 31, 2019 and 2018 respectively. As of January 31, 2019 and April 30, 2018 , property, plant and equipment included assets held under capital lease of $366,000 and $ 130,000 , respectively. Related depreciation expense was $37,000 and $7,000 for the three months ended January 31, 2019 and 2018 , respectively, and $ 80,000 and $ 20,000 for the nine months ended January 31, 2019 and 2018 , respectively. Capital Lease In November 2014, the Company entered into a capital lease for laboratory equipment. The lease has costs of approximately $149,000 and matures in November 2019. The current monthly capital lease payment is approximately $3,000 . In July 2018, the Company entered into a second capital lease for laboratory equipment. The lease has costs of approximately $266,000 with a monthly payment of approximately $11,000 . Although the lease was originally due to mature in July 2020, the Company decided to pay the outstanding balance on February 1, 2019. As a result, the entire outstanding balance is included as a current liability on the January 31, 2019 balance sheet. The following is a schedule by years of future minimum lease payments under both capital leases with the present value of the net minimum lease payments as of January 31, 2019 (table in thousands): For the Years Ended April 30, Total 2019 (remaining) $ 218 2020 16 Total minimum payments 234 Less: amount representing interest (10 ) Present value of minimum payments 224 Less: current portion (224 ) $ — The present value of minimum future obligations shown above is calculated based on an interest rate of 5% for the November 2014 lease and 7% for the July 2018 lease. The short-term and long-term components of the capital lease obligation are included in accrued liabilities and other non-current liabilities, respectively at January 31, 2019 and April 30, 2018 .

Share-Based Payments

Share-Based Payments	9 Months Ended
	Jan. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Payments	Share-Based Payments The Company has in place a 2010 Equity Incentive Plan and a 2008 Equity Incentive Plan. In general, these plans provide for stock-based compensation in the form of (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards. Stock-based compensation in the amount of $335,000 and $152,000 was recognized for the three months ended January 31, 2019 and 2018 , respectively. The increase in 2019 is due to the increased expense associated with stock options granted during the period. Stock-based compensation in the amount of $498,000 and $848,000 was recognized for the nine months ended January 31, 2019 and 2018 , respectively. Included in stock-based compensation expense for the nine months ended January 31, 2018 under general and administrative line item is an option modification charge of $57,000 . Stock-based compensation expense was recognized as follows (table in thousands): Three Months Ended Nine Months Ended 2019 2018 2019 2018 General and administrative $ 251 $ 110 $ 326 $ 614 Sales and marketing 53 7 100 47 Research and development 4 33 13 156 Cost of oncology services 27 2 59 31 Total stock-based compensation expense $ 335 $ 152 $ 498 $ 848 On January 31, 2019, there was $970,000 in unrecognized stock based compensation which will be recognized as expense over 4.3 years. Stock Option Grants Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2019 and 2018 were as follows: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Expected term in years 3-6 3 3-6 3-6 Risk-free interest rates 2.57% - 3.00% 1.98% 2.57% - 3.00% 1.77%-1.98% Volatility 64.55%-84.91% 85.59% 64.55%-84.91% 85.59%-87.66% Dividend yield —% —% —% —% The weighted average fair value of stock options granted during the three months ended January 31, 2019 and 2018 was $5.76 and $2.32 , respectively, and $ 6.03 and $ 1.95 for the nine months ended January 31, 2019 and 2018 , respectively. The Company’s stock options activity for the nine months ended January 31, 2019 was as follows: Non- Employees Directors and Employees Total Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, May 1, 2018 50,000 2,655,845 2,705,845 $ 2.85 5.9 $ 5,265,000 Granted — 206,790 206,790 9.86 8.1 — Exercised — (357,242 ) (357,242 ) 2.18 4.7 2,782,000 Forfeited — (8,375 ) (8,375 ) — Canceled — (40,183 ) (40,183 ) 2.10 370,626 Expired — (16,667 ) (16,667 ) — Outstanding, January 31, 2019 50,000 2,440,168 2,490,168 3.45 5.6 $ 22,036,000 Vested and expected to vest as of January 31, 2019 50,000 2,440,168 2,490,168 3.45 5.6 $ 22,036,000 Exercisable as of January 31, 2019 25,836 2,109,252 2,135,088 2.89 5.1 $ 20,087,000 Canceled shares represents a cashless payment for the net settlement of options exercised during the period. These shares were withheld by Champions Oncology, Inc. at the request of the option holder for payment of the exercise price based on the market price of Champions Oncology, Inc. common stock on the date of exercise and immediately canceled. Stock Purchase Warrants As of January 31, 2019 and April 30, 2018 , the Company had warrants outstanding for the purchase of 1,671,440 and 2,004,284 , respectively, shares of its common stock, all of which were exercisable. Activity related to these warrants, which expire at various dates through March 2020, is summarized as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, May 1, 2018 2,004,284 $ 5.57 1.8 $ — Granted — — — — Exercised (247,468 ) 5.16 — 668,195 Canceled (85,376 ) 4.80 — 628,128 Expired — — — — Outstanding, January 31, 2019 1,671,440 $ 5.58 1.1 $ 12,044,000 Canceled shares represents a cashless payment for the net settlement of warrants exercised during the period. These shares underlying the warrants were withheld by Champions Oncology, Inc. at the request of the warrant holder for payment of the exercise price based on the market price of Champions Oncology, Inc. common stock on the date of exercise and immediately canceled.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Jan. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Related party transactions include transactions between the Company and its shareholders, management, or affiliates. The following transactions were in the normal course of operations and were measured and recorded at the exchange amount, which is the amount of consideration established and agreed to by the parties. Consulting Services During each of the nine month periods ended January 31, 2019 and 2018 , the Company paid a member of its Board of Directors $54,000 , for consulting services unrelated to his duties as a board member. During the nine months ended January 31, 2019 and 2018 , the Company paid an affiliate of a board member $ 54,000 and $73,000 , respectively, for consulting services unrelated to his duty as a board member. As of January 31, 2019 , no amounts were due to these related parties.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jan. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases The Company currently leases its office facilities. Rent expenses totaled $583,000 and $480,000 for the nine months ended January 31, 2019 and 2018 , respectively. The Company considers its facilities adequate for our current operational needs. The Company leases the following facilities under non-cancelable operating lease agreements: • One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. The lease expires in November 2021 . The Company recognized $68,000 and $67,000 of rental costs relative to this lease for the nine months ended January 31, 2019 and 2018 , respectively. • 855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, which consists of laboratories and office space where the Company conducted operations related to its primary service offerings. This lease was terminated in October 2017 . The Company transitioned its activities from this location to 1330 Piccard Drive, Suite 025, Rockville, MD. The Company recognized nil and $59,000 of rental costs relative to this lease for the nine months ended January 31, 2019 and 2018 , respectively. • 450 East 29t h Street, New York, New York, 10016, which was a laboratory facility. The Company recognized nil and $52,000 of rental expense for the nine months ended January 31, 2019 and 2018 , respectively. The lease expired in May 2017 and was not renewed. • 1330 Piccard Drive, Suite 025, Rockville, MD 20850, which consists of laboratory and office space where the Company conducts operations related to its primary service offerings. The Company executed this lease on January 11, 2017. The operating commencement date was August 11, 2017. This lease expires in August 2028 . The Company recognized $453,000 and $302,000 of rental expense for the nine months ended January 31, 2019 and 2018 , respectively. • 910 Clopper Road, Suites 260S and 280S, Gaithersburg, Maryland 20878, which consists of laboratory and office space where the Company conducts operations related to its primary service offerings. The Company executed this lease on April 1, 2018. The operating commencement date was May 1, 2018. This lease expires in August 2028 . The Company recognized $41,000 and nil of rental expense for nine months ended January 31, 2019 and 2018 , respectively. The Company transitioned its activities from this location to the New Location, as defined below, and terminated this lease seven days after the commencement date of the New Location. • 1405 Research Boulevard, Suites 125, Rockville, Maryland 20850 (“New Location”), which consists of laboratory and office space where the Company conducts operations related to its primary service offerings. The Company executed this lease on November 1, 2018. The operating commencement date was January 17, 2019. This lease expires in January 2024 . The Company recognized $ 21,000 and nil of rental expense for the nine months ended January 31, 2019 and 2018 , respectively. Future minimum lease payments due each fiscal year as follows (in thousands): 2019 (remaining) $ 155 2020 1,077 2021 1,161 2022 1,139 2023 1,102 Thereafter 4,225 $ 8,859 Legal Matters The Company is not currently party to any legal matters to its knowledge. The Company is not aware of any other matters that would have a material impact on the Company’s financial position or results of operations.

Lines of Credit

Lines of Credit	9 Months Ended
	Jan. 31, 2019
Debt Disclosure [Abstract]
Lines of Credit	Lines of Credit On October 30, 2017, the Company entered into a line of credit agreement with a national bank which provides that the Company may borrow up to $1.5 million. The revolving line maturity date was October 29, 2018 and the line of credit was not renewed. The Company believes that such line of credit is not currently necessary to fund the Company's working capital needs.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Jan. 31, 2019
Accounting Policies [Abstract]
Recent Accounting Pronouncements	e Recognition All revenue is generated from contracts with customers. The Company's arrangements are service type contracts that mainly have a duration of less than a year. The Company recognizes revenue when control of these services is transferred to the customer in an amount, referred to as the transaction price, that reflects the consideration to which the Company is expected to be entitled in exchange for those services. The Company determines revenue recognition utilizing the following five steps: (1) identification of the contract with a customer, (2) identification of the performance obligations in the contract (promised goods or services that are distinct), (3) determination of the transaction price, (4) allocation of the transaction price to the performance obligations, and (5) recognition of revenue when, or as, the Company transfers control of the product or service for each performance obligation. The Company records revenues net of any tax assessments by governmental authorities, such as value added taxes, that are imposed on and concurrent with specific revenue generating transactions. Pharmacology Study, POS Services and Other Services The Company generally enters into contracts with customers to provide oncology services with payments based on fixed-fee arrangements. At contract inception, the Company assesses the services promised in the contracts with customers to identify the performance obligations in the arrangement. The Company's fixed-fee arrangements for oncology services are considered a single performance obligation because the Company provides a highly-integrated service. The Company recognizes revenue over time using a progress-based input method since there is no single output measure that would fairly depict the transfer of control over the life of the performance obligation. Revenue is recognized for the single performance obligation over time due to the Company's right to payment for work performed to date and the performance does not create an asset with an alternative use. The Company recognizes revenue as portions of the overall performance obligation are completed as this best depicts the progress of the performance obligation. Variable Consideration In some cases, contracts provide for variable consideration that is contingent upon the occurrence of uncertain future events, such as the success of the initial performance obligation. Variable consideration is estimated at the expected value or at the most likely amount depending on the type of consideration. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimate of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available to the Company. Trade Receivables, Unbilled Services and Deferred Revenue In general, billings and payments are established by contractual provisions including predetermined payment schedules, which may or may not correspond to the timing of the transfer of control of the Company's services under the contract. In general, the Company's intention in its invoicing (payment terms) is to maintain cash neutrality over the life of the contract. Upfront payments, when they occur, are intended to cover certain expenses the Company incurs at the beginning of the contract. Neither the Company nor its customers view such upfront payments and contracted payment schedules as a means of financing. Unbilled services primarily arise from timing of payment terms and when an input method of revenue recognition is utilized and revenue recognized exceeds the amount billed to the customer. Deferred revenue consists of unearned payments received in excess of revenue recognized. As the contracted services are subsequently performed and the associated revenue is recognized, the deferred revenue balance is reduced by the amount of the revenue recognized during the period. Deferred revenue is classified as a current liability on the condensed consolidated balance sheet as the Company expects to recognize the associated revenue in less than one year. Accounting Pronouncements Being Evaluated In August 2018, the FASB issued ASU 2018-15, which amends ASC 350-40, Intangibles—Goodwill and Other—Internal-Use Software, to address a customer’s accounting for implementation costs incurred in a cloud computing arrangement ("CCA") that is a service contract. This update aligns the accounting for costs incurred to implement a CCA that is a service arrangement with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The update is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption of the amendments in this update is permitted, including adoption in any interim period. We are currently assessing the impact of this update on our consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses". This update requires immediate recognition of management’s estimates of current expected credit losses ("CECL"). Under the prior model, losses were recognized only as they were incurred. The new model is applicable to all financial instruments that are not accounted for at fair value through net income. The standard is effective for fiscal years beginning after December 15, 2019 for public entities. Early adoption is permitted. We are currently assessing the impact of this update on our consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, "Leases". The Company is in the process of finalizing its evaluation of current leases and quantifying the impact to its balance sheet. The Company expects that the adoption of the standard will have a material impact on its consolidated balance sheet for the recognition of certain operating leases as right-of-use assets and lease liabilities. The Company does not expect the adoption of this standard to have a material impact on its consolidated statements of operations or cash flows. The Company will adopt the new accounting standard using the modified retrospective transition option on adoption on May 1, 2019. Recently Adopted Accounting Pronouncements In June 2018, the FASB issued ASU 2018-07, "Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting". This ASU expands the scope of Topic 718, Compensation—Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Under the new guidance, the existing employee guidance will apply to nonemployee sharebased transactions (as long as the transaction is not effectively a form of financing), with the exception of specific guidance related to the attribution of compensation cost. The cost of nonemployee awards will continue to be recorded as if the grantor had paid cash for the goods or services. The new accounting guidance will be effective for the Company on May 1, 2019. The Company has adopted this new rule beginning with its financial reporting for the quarter ended January 31, 2019. The adoption had no material impact on our consolidated financial statements. In August 2018, the Securities and Exchange Commission issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to the Company’s financial reporting is the inclusion of the annual disclosure requirement of changes in stockholders’ equity in Rule 3-04 of Regulation S-X to interim periods. The Company has adopted this new rule beginning with its financial reporting for the quarter ended October 31, 2018. On November 17, 2016, the FASB issued ASU No. 2016-18, "Restricted Cash (a consensus of the FASB Emerging Issues Task Force)" ("ASU 2016-18"), which addresses classification and presentation of changes in restricted cash on the statement of cash flows. ASU 2016-18 requires an entity's reconciliation of the beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include in cash and cash equivalents amounts generally described as restricted cash and restricted cash equivalents. ASU 2016-18 is effective for public business entities for annual and interim periods in fiscal years beginning after December 15, 2017. The Company adopted ASU 2016-18 on May 1, 2018. See "Note 2. Summary of Significant Accounting Policies" for additional disclosure. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. The new standard attempts to reduce diversity in practice in how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU No. 2016-15 provides guidance on eight specific cash flow issues. The new guidance was effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years. The Company adopted this update on May 1, 2018 and did not have a material impact on our consolidated financial statements. In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with customers ("ASU 2014-09"). The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The Company adopted ASU 2014-09 on May 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption and by recognizing the cumulative effect of applying the standard as an adjustment to the Company’s Balance Sheet. The adoption of this update did not have a material measurement impact on our consolidated financial statements. See "Note 4. Revenue from Contracts with Customers" for more information.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Jan. 31, 2019
Accounting Policies [Abstract]
New Accounting Pronouncements	Revenue Recognition All revenue is generated from contracts with customers. The Company's arrangements are service type contracts that mainly have a duration of less than a year. The Company recognizes revenue when control of these services is transferred to the customer in an amount, referred to as the transaction price, that reflects the consideration to which the Company is expected to be entitled in exchange for those services. The Company determines revenue recognition utilizing the following five steps: (1) identification of the contract with a customer, (2) identification of the performance obligations in the contract (promised goods or services that are distinct), (3) determination of the transaction price, (4) allocation of the transaction price to the performance obligations, and (5) recognition of revenue when, or as, the Company transfers control of the product or service for each performance obligation. The Company records revenues net of any tax assessments by governmental authorities, such as value added taxes, that are imposed on and concurrent with specific revenue generating transactions. Pharmacology Study, POS Services and Other Services The Company generally enters into contracts with customers to provide oncology services with payments based on fixed-fee arrangements. At contract inception, the Company assesses the services promised in the contracts with customers to identify the performance obligations in the arrangement. The Company's fixed-fee arrangements for oncology services are considered a single performance obligation because the Company provides a highly-integrated service. The Company recognizes revenue over time using a progress-based input method since there is no single output measure that would fairly depict the transfer of control over the life of the performance obligation. Revenue is recognized for the single performance obligation over time due to the Company's right to payment for work performed to date and the performance does not create an asset with an alternative use. The Company recognizes revenue as portions of the overall performance obligation are completed as this best depicts the progress of the performance obligation. Variable Consideration In some cases, contracts provide for variable consideration that is contingent upon the occurrence of uncertain future events, such as the success of the initial performance obligation. Variable consideration is estimated at the expected value or at the most likely amount depending on the type of consideration. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimate of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available to the Company. Trade Receivables, Unbilled Services and Deferred Revenue In general, billings and payments are established by contractual provisions including predetermined payment schedules, which may or may not correspond to the timing of the transfer of control of the Company's services under the contract. In general, the Company's intention in its invoicing (payment terms) is to maintain cash neutrality over the life of the contract. Upfront payments, when they occur, are intended to cover certain expenses the Company incurs at the beginning of the contract. Neither the Company nor its customers view such upfront payments and contracted payment schedules as a means of financing. Unbilled services primarily arise from timing of payment terms and when an input method of revenue recognition is utilized and revenue recognized exceeds the amount billed to the customer. Deferred revenue consists of unearned payments received in excess of revenue recognized. As the contracted services are subsequently performed and the associated revenue is recognized, the deferred revenue balance is reduced by the amount of the revenue recognized during the period. Deferred revenue is classified as a current liability on the condensed consolidated balance sheet as the Company expects to recognize the associated revenue in less than one year. Accounting Pronouncements Being Evaluated In August 2018, the FASB issued ASU 2018-15, which amends ASC 350-40, Intangibles—Goodwill and Other—Internal-Use Software, to address a customer’s accounting for implementation costs incurred in a cloud computing arrangement ("CCA") that is a service contract. This update aligns the accounting for costs incurred to implement a CCA that is a service arrangement with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The update is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption of the amendments in this update is permitted, including adoption in any interim period. We are currently assessing the impact of this update on our consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses". This update requires immediate recognition of management’s estimates of current expected credit losses ("CECL"). Under the prior model, losses were recognized only as they were incurred. The new model is applicable to all financial instruments that are not accounted for at fair value through net income. The standard is effective for fiscal years beginning after December 15, 2019 for public entities. Early adoption is permitted. We are currently assessing the impact of this update on our consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, "Leases". The Company is in the process of finalizing its evaluation of current leases and quantifying the impact to its balance sheet. The Company expects that the adoption of the standard will have a material impact on its consolidated balance sheet for the recognition of certain operating leases as right-of-use assets and lease liabilities. The Company does not expect the adoption of this standard to have a material impact on its consolidated statements of operations or cash flows. The Company will adopt the new accounting standard using the modified retrospective transition option on adoption on May 1, 2019. Recently Adopted Accounting Pronouncements In June 2018, the FASB issued ASU 2018-07, "Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting". This ASU expands the scope of Topic 718, Compensation—Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Under the new guidance, the existing employee guidance will apply to nonemployee sharebased transactions (as long as the transaction is not effectively a form of financing), with the exception of specific guidance related to the attribution of compensation cost. The cost of nonemployee awards will continue to be recorded as if the grantor had paid cash for the goods or services. The new accounting guidance will be effective for the Company on May 1, 2019. The Company has adopted this new rule beginning with its financial reporting for the quarter ended January 31, 2019. The adoption had no material impact on our consolidated financial statements. In August 2018, the Securities and Exchange Commission issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to the Company’s financial reporting is the inclusion of the annual disclosure requirement of changes in stockholders’ equity in Rule 3-04 of Regulation S-X to interim periods. The Company has adopted this new rule beginning with its financial reporting for the quarter ended October 31, 2018. On November 17, 2016, the FASB issued ASU No. 2016-18, "Restricted Cash (a consensus of the FASB Emerging Issues Task Force)" ("ASU 2016-18"), which addresses classification and presentation of changes in restricted cash on the statement of cash flows. ASU 2016-18 requires an entity's reconciliation of the beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include in cash and cash equivalents amounts generally described as restricted cash and restricted cash equivalents. ASU 2016-18 is effective for public business entities for annual and interim periods in fiscal years beginning after December 15, 2017. The Company adopted ASU 2016-18 on May 1, 2018. See "Note 2. Summary of Significant Accounting Policies" for additional disclosure. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. The new standard attempts to reduce diversity in practice in how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU No. 2016-15 provides guidance on eight specific cash flow issues. The new guidance was effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years. The Company adopted this update on May 1, 2018 and did not have a material impact on our consolidated financial statements. In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with customers ("ASU 2014-09"). The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The Company adopted ASU 2014-09 on May 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption and by recognizing the cumulative effect of applying the standard as an adjustment to the Company’s Balance Sheet. The adoption of this update did not have a material measurement impact on our consolidated financial statements. See "Note 4. Revenue from Contracts with Customers" for more information.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	9 Months Ended
	Jan. 31, 2019
Accounting Policies [Abstract]
Schedule of Cash and Restricted Cash	Cash and restricted cash consists of the following (table in thousands): January 31, 2019 April 30, 2018 (unaudited) Cash $ 3,310 $ 856 Restricted cash — 150 Total cash and restricted cash shown in the statement of cash flows $ 3,310 $ 1,006
Summary of the Calculation of Earnings per Share, Basic and Diluted	Three Months Ended Nine Months Ended January 31, 2019 2018 2019 2018 Basic and diluted net loss per share computation (dollars in thousands): Net income (loss) attributable to common stockholders $ (369 ) $ (76 ) $ 381 $ (844 ) Weighted Average common shares – basic 11,508,180 10,994,434 11,257,314 10,987,797 Basic net income (loss) per share $ (0.03 ) $ (0.01 ) $ 0.03 $ (0.08 ) Diluted income (loss) per share computation: Net income (loss) attributable to common stockholders $ (369 ) $ (76 ) $ 381 $ (844 ) Income (loss) available to common stockholders $ (369 ) $ (76 ) $ 381 $ (844 ) Weighted Average common shares 11,508,180 10,994,434 11,257,314 10,987,797 Incremental shares from assumed exercise of warrants and stock options — — 2,651,749 — Adjusted weighted average share – diluted 11,508,180 10,994,434 13,909,063 10,987,797 Diluted net income (loss) per share $ (0.03 ) $ (0.01 ) $ 0.03 $ (0.08 )
Summary of Antidilutive Securities Excluded from Earnings Per Share Calculations	The following table reflects the total potential share-based instruments outstanding at January 31, 2019 and 2018 that could have an effect on the future computation of dilution per common share: January 31, 2019 2018 Stock options 2,490,168 2,518,845 Warrants 1,671,440 2,004,284 Total common stock equivalents 4,161,608 4,523,129

Accounts Receivable, Unbilled_2

Accounts Receivable, Unbilled Services and Deferred Revenue (Tables)	9 Months Ended
	Jan. 31, 2019
Receivables [Abstract]
Summary of accounts receivable, unbilled services, and advanced billings	Accounts receivable and unbilled services were as follows (in thousands): January 31, 2019 April 30, 2018 (unaudited) Accounts receivable $ 2,367 $ 1,827 Unbilled services 1,565 2,103 Total accounts receivable and unbilled services 3,932 3,930 Less allowance for doubtful accounts (13 ) (13 ) Total accounts receivable, net $ 3,919 $ 3,917
Summary of advanced billings	was as follows (in thousands): January 31, 2019 April 30, 2018 (unaudited) Deferred revenue $ 4,723 $ 4,704

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	9 Months Ended
	Jan. 31, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables represents disaggregated revenue for the three and nine months ended January 31, 2019 and 2018 : Three Months Ended Nine Months Ended January 31, 2019 2018 2019 2018 Pharmacology services $ 5,988 $ 4,447 $ 18,037 $ 13,600 Personalized oncology services 416 259 1,024 1,077 Other 26 376 287 642 Total oncology services revenue $ 6,430 $ 5,082 $ 19,348 $ 15,319

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Jan. 31, 2019
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consisted of the following (table in thousands): January 31, April 30, (unaudited) Furniture and fixtures $ 127 $ 73 Computer equipment and software 1,086 973 Laboratory equipment 3,241 2,490 Assets in progress 25 15 Total property and equipment 4,479 3,551 Less: Accumulated depreciation (1,901 ) (1,468 ) Property and equipment, net $ 2,578 $ 2,083
Schedule of Future Minimum Payment for Capital Leases	The following is a schedule by years of future minimum lease payments under both capital leases with the present value of the net minimum lease payments as of January 31, 2019 (table in thousands): For the Years Ended April 30, Total 2019 (remaining) $ 218 2020 16 Total minimum payments 234 Less: amount representing interest (10 ) Present value of minimum payments 224 Less: current portion (224 ) $ —

Share-Based Payments (Tables)

Share-Based Payments (Tables)	9 Months Ended
	Jan. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Allocation of Share Based Compensation Expense	Stock-based compensation expense was recognized as follows (table in thousands): Three Months Ended Nine Months Ended 2019 2018 2019 2018 General and administrative $ 251 $ 110 $ 326 $ 614 Sales and marketing 53 7 100 47 Research and development 4 33 13 156 Cost of oncology services 27 2 59 31 Total stock-based compensation expense $ 335 $ 152 $ 498 $ 848
Valuation Assumptions for Stock Options	Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2019 and 2018 were as follows: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Expected term in years 3-6 3 3-6 3-6 Risk-free interest rates 2.57% - 3.00% 1.98% 2.57% - 3.00% 1.77%-1.98% Volatility 64.55%-84.91% 85.59% 64.55%-84.91% 85.59%-87.66% Dividend yield —% —% —% —%
Summary of Stock Option Activity	The Company’s stock options activity for the nine months ended January 31, 2019 was as follows: Non- Employees Directors and Employees Total Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, May 1, 2018 50,000 2,655,845 2,705,845 $ 2.85 5.9 $ 5,265,000 Granted — 206,790 206,790 9.86 8.1 — Exercised — (357,242 ) (357,242 ) 2.18 4.7 2,782,000 Forfeited — (8,375 ) (8,375 ) — Canceled — (40,183 ) (40,183 ) 2.10 370,626 Expired — (16,667 ) (16,667 ) — Outstanding, January 31, 2019 50,000 2,440,168 2,490,168 3.45 5.6 $ 22,036,000 Vested and expected to vest as of January 31, 2019 50,000 2,440,168 2,490,168 3.45 5.6 $ 22,036,000 Exercisable as of January 31, 2019 25,836 2,109,252 2,135,088 2.89 5.1 $ 20,087,000
Summary of Warrant Activity	Activity related to these warrants, which expire at various dates through March 2020, is summarized as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, May 1, 2018 2,004,284 $ 5.57 1.8 $ — Granted — — — — Exercised (247,468 ) 5.16 — 668,195 Canceled (85,376 ) 4.80 — 628,128 Expired — — — — Outstanding, January 31, 2019 1,671,440 $ 5.58 1.1 $ 12,044,000

Commitments and Contingencies

Commitments and Contingencies (Tables)	9 Months Ended
	Jan. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments	Future minimum lease payments due each fiscal year as follows (in thousands): 2019 (remaining) $ 155 2020 1,077 2021 1,161 2022 1,139 2023 1,102 Thereafter 4,225 $ 8,859

Organization, Use of Estimate_2

Organization, Use of Estimates and Basis of Presentation - Narrative (Details)	9 Months Ended
	Jan. 31, 2019subsidiary
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating subsidiaries	2

Significant Accounting Polici_4

Significant Accounting Policies - Narrative (Details) - USD ($)	3 Months Ended				9 Months Ended
	Jan. 31, 2019	Oct. 31, 2018	Jul. 31, 2018	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018	Apr. 30, 2018
Accounting Policies [Abstract]
Restricted cash	$ 0				$ 0		$ 150,000
Net income (loss)	(369,000)	$ 267,000	$ 483,000	$ (76,000)	381,000	$ (844,000)
Net cash used in operating activities					(1,610,000)	1,235,000
Accumulated deficit	(70,445,000)				(70,445,000)		(70,826,000)
Positive working capital	(177,000)				(177,000)
Cash and cash equivalents	3,310,000				3,310,000
Unrecognized tax benefits	151,000				151,000		$ 151,000
Provision for income taxes	$ 0			$ 2,000	$ 0	$ 18,000

Significant Accounting Polici_5

Significant Accounting Policies - Cash and Restricted Cash (Details) - USD ($) $ in Thousands	Jan. 31, 2019	Apr. 30, 2018	Jan. 31, 2018	Apr. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 3,310	$ 856
Restricted cash	0	150
Total cash and restricted cash shown in the statement of cash flows	$ 3,310	$ 1,006	$ 1,062	$ 3,295

Significant Accounting Polici_6

Significant Accounting Policies - Calculation of Earnings Per Share (Details) - USD ($)	3 Months Ended				9 Months Ended
	Jan. 31, 2019	Oct. 31, 2018	Jul. 31, 2018	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Basic loss per share computation
Net income (loss) attributable to common stockholders	$ (369,000)	$ 267,000	$ 483,000	$ (76,000)	$ 381,000	$ (844,000)
Weighted Average common shares - basic (in shares)	11,508,180			10,994,434	11,257,314	10,987,797
Basic net income (loss) per share (in dollars per share)	$ (0.03)			$ (0.01)	$ 0.03	$ (0.08)
Income (loss) available to common stockholders	$ (369,000)			$ (76,000)	$ 381,000	$ (844,000)
Incremental shares from assumed exercise of warrants and stock options (in shares)	0			0	2,651,749	0
Adjusted weighted average share - diluted (in shares)	11,508,180			10,994,434	13,909,063	10,987,797
Diluted net income (loss) per share (in usd per share)	$ (0.03)			$ (0.01)	$ 0.03	$ (0.08)

Significant Accounting Polici_7

Significant Accounting Policies - Summary of Potentially Antidilutive Securities (Details) - shares	9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents	4,161,608	4,523,129
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents	2,490,168	2,518,845
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents	1,671,440	2,004,284

Accounts Receivable, Unbilled_3

Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Accounts Receivable and Unbilled Services (Details) - USD ($) $ in Thousands	Jan. 31, 2019	Apr. 30, 2018
Receivables [Abstract]
Accounts receivable	$ 2,367	$ 1,827
Unbilled services	1,565	2,103
Total accounts receivable and unbilled services	3,932	3,930
Less allowance for doubtful accounts	(13)	(13)
Total accounts receivable, net	$ 3,919	$ 3,917

Accounts Receivable, Unbilled_4

Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Deferred Revenue (Details) - USD ($) $ in Thousands	Jan. 31, 2019	Apr. 30, 2018
Receivables [Abstract]
Deferred revenue	$ 4,723	$ 4,704

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Disaggregation of Revenue [Line Items]
Oncology services revenue	$ 6,430	$ 5,082	$ 19,348	$ 15,319
Pharmacology services
Disaggregation of Revenue [Line Items]
Oncology services revenue	5,988	4,447	18,037	13,600
Personalized oncology services
Disaggregation of Revenue [Line Items]
Oncology services revenue	416	259	1,024	1,077
Other
Disaggregation of Revenue [Line Items]
Oncology services revenue	$ 26	$ 376	$ 287	$ 642

Property and Equipment - Narrat

Property and Equipment - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Jul. 31, 2018	Nov. 30, 2014	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018	Apr. 30, 2018
Property, Plant and Equipment [Line Items]
Depreciation			$ 127	$ 98	$ 353	$ 233
Capital leased assets, gross			366		366		$ 130
Capital leases monthly payments	$ 11	$ 3
Assets Held under Capital Leases
Property, Plant and Equipment [Line Items]
Depreciation			$ 37	$ 7	$ 80	$ 20
Equipment Leased to Other Party
Property, Plant and Equipment [Line Items]
Capital lease asset	$ 266	$ 149
November 2014 Lease
Property, Plant and Equipment [Line Items]
Capital leases of lessee, contingent rentals, basis spread on variable rate			5.00%		5.00%
July 2018 Lease
Property, Plant and Equipment [Line Items]
Capital leases of lessee, contingent rentals, basis spread on variable rate			7.00%		7.00%
Minimum
Property, Plant and Equipment [Line Items]
Useful lives					3 years
Maximum
Property, Plant and Equipment [Line Items]
Useful lives					7 years

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Jan. 31, 2019	Apr. 30, 2018
Property, Plant and Equipment [Abstract]
Furniture and fixtures	$ 127	$ 73
Computer equipment and software	1,086	973
Laboratory equipment	3,241	2,490
Assets in progress	25	15
Total property and equipment	4,479	3,551
Less: Accumulated depreciation	(1,901)	(1,468)
Property and equipment, net	$ 2,578	$ 2,083

Property and Equipment - Schedu

Property and Equipment - Schedule of Future Minimum Payments for Capital Leases (Details) $ in Thousands	Jan. 31, 2019USD ($)
Property, Plant and Equipment [Abstract]
2019 (remaining)	$ 218
2020	16
Total minimum payments	234
Less: amount representing interest	(10)
Present value of minimum payments	224
Less: current portion	(224)
Capital Lease, noncurrent	$ 0

Share-Based Payments - Narrativ

Share-Based Payments - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018	Apr. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 335,000	$ 152,000	$ 498,000	$ 848,000
Option modification charge		$ 57,000
Unrecognized compensation cost	$ 970,000		$ 970,000
Period for recognition			4 years 3 months
Weighted-average grant date fair value (in usd per share)	$ 5.76	$ 2.32	$ 6.03	$ 1.95
Warrants outstanding (in shares)	1,671,440		1,671,440		2,004,284

Share-Based Payments - Allocati

Share-Based Payments - Allocation of Share Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 335	$ 152	$ 498	$ 848
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	251	110	326	614
Sales and marketing
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	53	7	100	47
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	4	33	13	156
Cost of oncology services
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 27	$ 2	$ 59	$ 31

Share-Based Payments - Valuatio

Share-Based Payments - Valuation Assumptions for Stock Options (Details)	3 Months Ended		9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term in years	6 years
Risk-free interest rates		1.98%
Volatility		85.60%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term in years	3 years		3 years	3 years
Risk-free interest rates	2.57%		2.71%	1.77%
Volatility	64.55%		64.55%	85.59%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term in years		3 years	6 years	6 years
Risk-free interest rates	3.00%		3.00%	1.98%
Volatility	84.91%		84.91%	87.66%

Share-Based Payments - Summary

Share-Based Payments - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Jan. 31, 2019	Apr. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Shares, Outstanding, Beginning Balance	2,705,845
Shares, Granted	206,790
Shares, Exercised	(357,242)
Shares, Forfeited	(8,375)
Shares, Canceled	(40,183)
Shares, Expired	(16,667)
Shares, Outstanding, Ending Balance	2,490,168	2,705,845
Shares, Vested and expected to vest	2,490,168
Shares, Exercisable	2,135,088
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price, Outstanding, Beginning Balance (in usd per share)	$ 2.85
Weighted Average Exercise Price, Granted (in usd per share)	9.86
Weighted Average Exercise Price, Exercised (in usd per share)	2.18
Weighted Average Exercise Price, Forfeited (in usd per share)	0
Weighted Average Exercise Price, Canceled (in usd per share)	2.10
Weighted Average Exercise Price, Expired (in usd per share)	0
Weighted Average Exercise Price, Outstanding, Ending Balance (in usd per share)	3.45	$ 2.85
Weighted Average Exercise Price, Vested and expected to vest (in usd per share)	3.45
Weighted Average Exercise Price, Exercisable (in usd per share)	$ 2.89
Weighted Average Remaining Contractual Term, Outstanding, Beginning Balance (in years)		5 years 10 months 25 days
Weighted Average Remaining Contractual Life, Granted (in years)	8 years 1 month 18 days
Weighted Average Remaining Contractual Life, Exercised (in years)	4 years 8 months 18 days
Weighted Average Remaining Contractual Term, Outstanding, Ending Balance (in years)	5 years 6 months 25 days
Weighted Average Remaining Contractual Life, Vested and expected to vest (in years)	5 years 6 months 25 days
Weighted Average Remaining Contractual Life, Exercisable (in years)	5 years 1 month 24 days
Aggregate Intrinsic Value, Outstanding, Beginning Balance	$ 5,265
Aggregate Intrinsic Value, Granted	0
Aggregate Intrinsic Value, Exercised	$ 2,782
Aggregate Intrinsic Value, Canceled	$ 370,626
Aggregate Intrinsic Value, Outstanding, Ending Balance	$ 22,036	$ 5,265
Aggregate Intrinsic Value, Vested and expected to vest	22,036
Aggregate Intrinsic Value, Exercisable	$ 20,087
Non-employees
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Shares, Outstanding, Beginning Balance	50,000
Shares, Granted	0
Shares, Exercised	0
Shares, Forfeited	0
Shares, Canceled	0
Shares, Expired	0
Shares, Outstanding, Ending Balance	50,000	50,000
Shares, Vested and expected to vest	50,000
Shares, Exercisable	25,836
Directors and employees
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Shares, Outstanding, Beginning Balance	2,655,845
Shares, Granted	206,790
Shares, Exercised	(357,242)
Shares, Forfeited	(8,375)
Shares, Canceled	(40,183)
Shares, Expired	(16,667)
Shares, Outstanding, Ending Balance	2,440,168	2,655,845
Shares, Vested and expected to vest	2,440,168
Shares, Exercisable	2,109,252

Share-Based Payments - Summar_2

Share-Based Payments - Summary of Warrant Activity (Details) - USD ($)	9 Months Ended	12 Months Ended
	Jan. 31, 2019	Apr. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Aggregate Intrinsic Value, Exercised	$ 668,195
Aggregate Intrinsic Value, Canceled	$ 628,128
Warrants
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of Shares, Beginning Balance	2,004,284
Number of Shares, Granted	0
Number of Shares, Exercised	(247,468)
Number of Shares, Canceled	(85,376)
Number of Shares, Expired	0
Number of Shares, Ending Balance	1,671,440	2,004,284
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Exercise Price, Beginning Balance (in usd per share)	$ 5.57
Weighted Average Exercise Price, Granted (in usd per share)	0
Weighted Average Exercise Price, Exercised (in usd per share)	5.16
Weighted Average Exercise Price, Canceled (in usd per share)	4.80
Weighted Average Exercise Price, Expired (in usd per share)	0
Weighted Average Exercise Price, Ending Balance (in usd per share)	$ 5.58	$ 5.57
Weighted Average Remaining Contractual Life (in years)	1 year 1 month 13 days	1 year 9 months 18 days
Aggregate Intrinsic Value, Beginning Balance	$ 0
Aggregate Intrinsic Value, Ending Balance	$ 12,044,000	$ 0

Related Party Transactions - Na

Related Party Transactions - Narrative (Details) - USD ($)	9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Board of directors chairman
Related Party Transaction [Line Items]
Related related party transaction, amounts of transaction	$ 54,000	$ 54,000
Substantial stockholders
Related Party Transaction [Line Items]
Related related party transaction, amounts of transaction	$ 54,000	$ 73,000

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details) - USD ($)	9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Commitments and Contingencies [Line Items]
Operating leases, rent expense	$ 583,000	$ 480,000
Corporate headquarters
Commitments and Contingencies [Line Items]
Operating leases, rent expense	68,000	67,000
Laboratories and office space
Commitments and Contingencies [Line Items]
Operating leases, rent expense	0	59,000
New York laboratory
Commitments and Contingencies [Line Items]
Operating leases, rent expense	0	52,000
Rockville, MD
Commitments and Contingencies [Line Items]
Operating leases, rent expense	453,000	302,000
Gaithersburg, MD
Commitments and Contingencies [Line Items]
Operating leases, rent expense	$ 41,000	$ 0

Commitments and Contingencies_2

Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Jan. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019 (remaining)	$ 155
2020	1,077
2021	1,161
2022	1,139
2023	1,102
Thereafter	4,225
Total	$ 8,859

Lines of Credit - Narrative (De

Lines of Credit - Narrative (Details)	Oct. 30, 2017USD ($)
Debt Disclosure [Abstract]
Credit facility	$ 1,500,000